サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1489271

ギランバレー症候群（GBS）の世界市場調査レポート：産業分析、規模、シェア、成長、動向、2024年から2032年までの予測

Global Guillain-Barre Syndrome (GBS) Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日
ページ情報
英文 224 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
ギランバレー症候群（GBS）の世界市場調査レポート：産業分析、規模、シェア、成長、動向、2024年から2032年までの予測
出版日: 2024年05月01日
発行: Value Market Research
ページ情報: 英文 224 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ギランバレー症候群（GBS）市場の世界需要は、2023年の6億7,262万米ドルから2032年には10億5,424万米ドル近くの市場規模に達すると推定され、調査期間2024年のCAGRは5.12%です。

ギランバレー症候群（GBS）は、免疫系が末梢神経を標的とし、筋力低下や麻痺を引き起こす珍しい自己免疫疾患です。症状はしばしば足のしびれや脱力感から始まり、進行すると全身に影響を及ぼします。通常、感染症がGBSの引き金となり、回復には免疫療法や理学療法などの治療が必要となります。より良い転帰を得るためには、早期の診断と介入が不可欠です。

市場力学

ギランバレー症候群（GBS）市場は、この疾患の診断、治療、調査に影響を与える様々な要因によって牽引されています。ギランバレー症候群（GBS）に対する医療従事者や一般市民の認識が高まり、早期診断と早期介入につながりました。ジカウイルスや最近ではCOVID-19のような感染症に関連してGBSの有病率が上昇していることから、この症候群への関心が高まっています。医学研究と技術の進歩によりGBSに対する理解が深まり、より効果的な治療法や治療法が開発されています。GBSの主な治療法である免疫グロブリン療法とプラズマフェレシスは大きな進歩を遂げ、その有効性と利用しやすさが向上しました。

希少疾患研究のための政府および民間資金援助もまた、技術革新と新たな治療法の選択肢を促進することにより、GBS市場の成長を支えています。さらに、専門ヘルスケア施設の増加や高度な診断ツールの利用可能性も、GBSの管理向上に寄与しています。ヘルスケアプロバイダー、研究者、患者支援団体の協力体制は、ギランバレー症候群（GBS）の認知度を高め、罹患者を支援する上で不可欠であり、市場の成長を後押ししています。しかし、一部の地域では認知度が低く、診断が遅れていることが、今後数年間の市場成長の課題となる可能性があります。

この調査レポートは、ポーターのファイブフォースモデル、市場魅力度分析、バリューチェーン分析を対象としています。これらのツールは、業界の構造を明確に把握し、世界レベルでの競合の魅力を評価するのに役立ちます。さらに、これらのツールは、ギランバレー症候群（GBS）の世界市場における各セグメントを包括的に評価することもできます。ギランバレー症候群（GBS）産業の成長と動向は、この調査の全体的なアプローチを提供します。

地域別分析

本セクションでは、北米、欧州、アジア太平洋、ラテンアメリカ、中東アフリカにおけるギランバレー症候群（GBS）市場の現在および将来の需要を強調する地域展望をカバーします。さらに、本レポートでは、著名な全地域における個々のアプリケーションセグメントの需要・推定・予測に焦点を当てています。

カスタム要件がある場合は、お問い合わせください。当社の調査チームは、お客様のニーズに応じてカスタマイズしたレポートを提供することができます。

目次

第1章 序文

第2章 エグゼクティブサマリー

  • 市場のハイライト
  • 世界市場スナップショット

第3章 ギランバレー症候群（GBS）-産業分析

  • イントロダクション：市場力学
  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 産業動向
  • ポーターのファイブフォース分析
  • 市場魅力度分析

第4章 バリューチェーン分析

  • バリューチェーン分析
  • 原材料分析
    • 原材料リスト
    • 原材料メーカーリスト
    • 主要原材料の価格動向
  • 潜在的バイヤーのリスト
  • マーケティングチャネル
    • ダイレクトマーケティング
    • インダイレクトマーケティング
    • マーケティングチャネル発展動向

第5章 ギランバレー症候群（GBS）の世界市場分析：治療タイプ別

  • 治療タイプ別概要
  • 実績データと予測データ
  • 治療タイプ別分析
  • 第一選択治療（免疫グロブリン静注（IVIG）、血漿交換（プラズマフェレーシス））
  • 支持療法

第6章 ギランバレー症候群（GBS）の世界市場分析：タイプ別

  • タイプ別概要
  • 実績データと予測データ
  • タイプ別分析
  • 急性炎症性脱髄性多発神経炎（AIDP）
  • 慢性炎症性脱髄性多発神経炎（CIDP）
  • ミラーフィッシャー症候群（MFS）
  • 急性運動軸索神経障害（AMAN）
  • その他のタイプ

第7章 ギランバレー症候群（GBS）の世界市場分析：性別

  • 性別概要
  • 実績データと予測データ
  • 性別分析
  • 男性
  • 女性

第8章 ギランバレー症候群（GBS）の世界市場分析：年齢層別

  • 年齢層別概要
  • 実績データと予測データ
  • 年齢層別分析
  • 20歳未満
  • 21-40歳
  • 41-59歳
  • 60歳以上

第9章 ギランバレー症候群（GBS）の世界市場分析：エンドユーザー別

  • エンドユーザー別概要
  • 実績データと予測データ
  • エンドユーザー別分析
  • 病院
  • 診療所
  • リハビリセンター
  • その他のエンドユーザー

第10章 ギランバレー症候群（GBS）の世界市場分析：地域別

  • 地域別展望
  • イントロダクション
  • 北米の売上分析
    • 概要、実績と予測
    • 北米：セグメント別
    • 北米：国別
    • 米国
    • カナダ
    • メキシコ
  • 欧州売上分析
    • 概要、実績と予測
    • 欧州：セグメント別
    • 欧州：国別
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • ロシア
    • その他欧州
  • アジア太平洋地域売上分析
    • 概要、実績と予測
    • アジア太平洋地域：セグメント別
    • アジア太平洋地域：国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • 東南アジア
    • その他アジア太平洋地域
  • ラテンアメリカ売上分析
    • 概要、実績と予測
    • ラテンアメリカ：セグメント別
    • ラテンアメリカ：国別
    • ブラジル
    • アルゼンチン
    • ペルー
    • チリ
    • その他ラテンアメリカ
  • 中東・アフリカ売上分析
    • 概要、実績と予測
    • 中東・アフリカ：セグメント別
    • 中東・アフリカ：国別
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他中東とアフリカ

第11章 ギランバレー症候群（GBS）企業の競合情勢

  • ギランバレー症候群（GBS）市場競争
  • 提携・協力・合意
  • 合併・買収
  • 新製品上市
  • その他の開発

第12章 企業プロファイル

  • 上位企業の市場シェア分析
  • 市場集中度
  • AbbVie Inc.
  • Biogen Inc.
  • Cadila Healthcare Limited
  • CSL Behring LLC
  • F.Hoffmann-La Roche Ltd.
  • GSK Plc
  • Grifols SA
  • LGM Pharmaceuticals Inc.
  • Merck & Co. Inc.
  • Octapharma AG
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
図表

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Treatment Type (USD MN)
  • First-line Treatment (Intravenous immunoglobulin (IVIG), Plasma exchange (Plasmapheresis)) Market Sales By Geography (USD MN)
  • Supportive treatment Market Sales By Geography (USD MN)
  • Analysis By Type (USD MN)
  • Acute Inflammatory Demyelinating Polyneuropathy (AIDP) Market Sales By Geography (USD MN)
  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Market Sales By Geography (USD MN)
  • Miller Fisher Syndrome (MFS) Market Sales By Geography (USD MN)
  • Acute Motor Axonal Neuropathy (AMAN) Market Sales By Geography (USD MN)
  • Other Types Market Sales By Geography (USD MN)
  • Analysis By Gender (USD MN)
  • Male Market Sales By Geography (USD MN)
  • Female Market Sales By Geography (USD MN)
  • Analysis By Age Group (USD MN)
  • Below 20 years Market Sales By Geography (USD MN)
  • 21-40 years Market Sales By Geography (USD MN)
  • 41-59 years Market Sales By Geography (USD MN)
  • 60 and above Market Sales By Geography (USD MN)
  • Analysis By End-user (USD MN)
  • Hospitals Market Sales By Geography (USD MN)
  • Clinics Market Sales By Geography (USD MN)
  • Rehabilitation Centers Market Sales By Geography (USD MN)
  • Other end-users Market Sales By Geography (USD MN)
  • Global Guillain-Barre Syndrome (GBS) Market Sales By Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United States Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate By Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Guillain-Barre Syndrome (GBS) Report
  • Market Research Process
  • Market Research Methodology
  • Global Guillain-Barre Syndrome (GBS) Market Size, By Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Treatment Type
  • Market Attractiveness Analysis By Type
  • Market Attractiveness Analysis By Gender
  • Market Attractiveness Analysis By Age Group
  • Market Attractiveness Analysis By End-user
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Treatment Type (USD MN)
  • First-line Treatment (Intravenous immunoglobulin (IVIG), Plasma exchange (Plasmapheresis)) Market Sales By Geography (USD MN)
  • Supportive treatment Market Sales By Geography (USD MN)
  • Global Market Analysis By Type (USD MN)
  • Acute Inflammatory Demyelinating Polyneuropathy (AIDP) Market Sales By Geography (USD MN)
  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Market Sales By Geography (USD MN)
  • Miller Fisher Syndrome (MFS) Market Sales By Geography (USD MN)
  • Acute Motor Axonal Neuropathy (AMAN) Market Sales By Geography (USD MN)
  • Other Types Market Sales By Geography (USD MN)
  • Global Market Analysis By Gender (USD MN)
  • Male Market Sales By Geography (USD MN)
  • Female Market Sales By Geography (USD MN)
  • Global Market Analysis By Age Group (USD MN)
  • Below 20 years Market Sales By Geography (USD MN)
  • 21-40 years Market Sales By Geography (USD MN)
  • 41-59 years Market Sales By Geography (USD MN)
  • 60 and above Market Sales By Geography (USD MN)
  • Global Market Analysis By End-user (USD MN)
  • Hospitals Market Sales By Geography (USD MN)
  • Clinics Market Sales By Geography (USD MN)
  • Rehabilitation Centers Market Sales By Geography (USD MN)
  • Other end-users Market Sales By Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

目次
Product Code: VMR112114696

The global demand for Guillain-Barre Syndrome (GBS) Market is presumed to reach the market size of nearly USD 1054.24 Million by 2032 from USD 672.62 Million in 2023 with a CAGR of 5.12% under the study period 2024-2032.

Guillain-Barre syndrome (GBS) is an uncommon autoimmune disorder in which the immune system targets the peripheral nerves, leading to muscle weakness and paralysis. Symptoms often begin with tingling & weakness in the legs and can progress to affect the entire body. An infection typically triggers GBS and requires medical treatment such as immunotherapy and physical therapy for recovery. Early diagnosis and intervention are vital for better outcomes.

MARKET DYNAMICS

The guillain-barre syndrome (GBS) market is driven by various factors influencing the diagnosis, treatment, and research associated with this condition. Spurring awareness among healthcare professionals and the public about guillain-barre syndrome (GBS)has led to earlier diagnosis and intervention, which is crucial for better patient outcomes. The rising prevalence of GBS, often linked to infections like the Zika virus and, more recently, COVID-19, has heightened the focus on this syndrome. Medical research and technology advances have improved the understanding of GBS, leading to more effective treatments and therapies. Immunoglobulin therapy and plasmapheresis, the primary treatments for GBS, have seen significant advancements, enhancing their efficacy and accessibility.

Government and private funding for rare disease research also supports the growth of the GBS market by fostering innovation and new treatment options. Furthermore, the increasing number of specialized healthcare facilities and the availability of advanced diagnostic tools contribute to the improved management of GBS. Collaborative efforts among healthcare providers, researchers, and patient advocacy groups are vital in driving awareness and supporting those affected by guillain-barre syndrome (GBS), propelling the market growth. However, limited awareness and late diagnosis in certain regions may challenge the market growth in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Guillain-Barre Syndrome (GBS). The growth and trends of Guillain-Barre Syndrome (GBS) industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Guillain-Barre Syndrome (GBS) market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Treatment Type

  • First-line Treatment (Intravenous immunoglobulin (IVIG), Plasma exchange (Plasmapheresis))
  • Supportive treatment

By Type

  • Acute Inflammatory Demyelinating Polyneuropathy (AIDP)
  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
  • Miller Fisher Syndrome (MFS)
  • Acute Motor Axonal Neuropathy (AMAN)
  • Other Types

By Gender

  • Male
  • Female

By Age Group

  • Below 20 years
  • 21-40 years
  • 41-59 years
  • 60 and above

By End-user

  • Hospitals
  • Clinics
  • Rehabilitation Centers
  • Other end-users

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Guillain-Barre Syndrome (GBS) market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Guillain-Barre Syndrome (GBS) market include AbbVie Inc., Biogen Inc., Cadila Healthcare Limited, CSL Behring LLC, F.Hoffmann-La Roche Ltd., GSK Plc, Grifols SA, LGM Pharmaceuticals Inc., Merck & Co. Inc., Octapharma AG, Pfizer Inc., Takeda Pharmaceutical Company Limited. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. GUILLAIN-BARRE SYNDROME (GBS) - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Treatment Type
    • 3.7.2 Market Attractiveness Analysis By Type
    • 3.7.3 Market Attractiveness Analysis By Gender
    • 3.7.4 Market Attractiveness Analysis By Age Group
    • 3.7.5 Market Attractiveness Analysis By End-user
    • 3.7.6 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL GUILLAIN-BARRE SYNDROME (GBS) MARKET ANALYSIS BY TREATMENT TYPE

  • 5.1. Overview By Treatment Type
  • 5.2. Historical and Forecast Data
  • 5.3. Analysis By Treatment Type
  • 5.4. First-line Treatment (Intravenous immunoglobulin (IVIG), Plasma exchange (Plasmapheresis)) Historic and Forecast Sales By Regions
  • 5.5. Supportive treatment Historic and Forecast Sales By Regions

6. GLOBAL GUILLAIN-BARRE SYNDROME (GBS) MARKET ANALYSIS BY TYPE

  • 6.1. Overview By Type
  • 6.2. Historical and Forecast Data
  • 6.3. Analysis By Type
  • 6.4. Acute Inflammatory Demyelinating Polyneuropathy (AIDP) Historic and Forecast Sales By Regions
  • 6.5. Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Historic and Forecast Sales By Regions
  • 6.6. Miller Fisher Syndrome (MFS) Historic and Forecast Sales By Regions
  • 6.7. Acute Motor Axonal Neuropathy (AMAN) Historic and Forecast Sales By Regions
  • 6.8. Other Types Historic and Forecast Sales By Regions

7. GLOBAL GUILLAIN-BARRE SYNDROME (GBS) MARKET ANALYSIS BY GENDER

  • 7.1. Overview By Gender
  • 7.2. Historical and Forecast Data
  • 7.3. Analysis By Gender
  • 7.4. Male Historic and Forecast Sales By Regions
  • 7.5. Female Historic and Forecast Sales By Regions

8. GLOBAL GUILLAIN-BARRE SYNDROME (GBS) MARKET ANALYSIS BY AGE GROUP

  • 8.1. Overview By Age Group
  • 8.2. Historical and Forecast Data
  • 8.3. Analysis By Age Group
  • 8.4. Below 20 years Historic and Forecast Sales By Regions
  • 8.5. 21-40 years Historic and Forecast Sales By Regions
  • 8.6. 41-59 years Historic and Forecast Sales By Regions
  • 8.7. 60 and above Historic and Forecast Sales By Regions

9. GLOBAL GUILLAIN-BARRE SYNDROME (GBS) MARKET ANALYSIS BY END-USER

  • 9.1. Overview By End-user
  • 9.2. Historical and Forecast Data
  • 9.3. Analysis By End-user
  • 9.4. Hospitals Historic and Forecast Sales By Regions
  • 9.5. Clinics Historic and Forecast Sales By Regions
  • 9.6. Rehabilitation Centers Historic and Forecast Sales By Regions
  • 9.7. Other end-users Historic and Forecast Sales By Regions

10. GLOBAL GUILLAIN-BARRE SYNDROME (GBS) MARKET ANALYSIS BY GEOGRAPHY

  • 10.1. Regional Outlook
  • 10.2. Introduction
  • 10.3. North America Sales Analysis
    • 10.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 10.3.2 North America By Segment Sales Analysis
    • 10.3.3 North America By Country Sales Analysis
    • 10.3.4 United States Sales Analysis
    • 10.3.5 Canada Sales Analysis
    • 10.3.6 Mexico Sales Analysis
  • 10.4. Europe Sales Analysis
    • 10.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 10.4.2 Europe By Segment Sales Analysis
    • 10.4.3 Europe By Country Sales Analysis
    • 10.4.4 United Kingdom Sales Analysis
    • 10.4.5 France Sales Analysis
    • 10.4.6 Germany Sales Analysis
    • 10.4.7 Italy Sales Analysis
    • 10.4.8 Russia Sales Analysis
    • 10.4.9 Rest Of Europe Sales Analysis
  • 10.5. Asia Pacific Sales Analysis
    • 10.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 10.5.2 Asia Pacific By Segment Sales Analysis
    • 10.5.3 Asia Pacific By Country Sales Analysis
    • 10.5.4 China Sales Analysis
    • 10.5.5 India Sales Analysis
    • 10.5.6 Japan Sales Analysis
    • 10.5.7 South Korea Sales Analysis
    • 10.5.8 Australia Sales Analysis
    • 10.5.9 South East Asia Sales Analysis
    • 10.5.10 Rest Of Asia Pacific Sales Analysis
  • 10.6. Latin America Sales Analysis
    • 10.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 10.6.2 Latin America By Segment Sales Analysis
    • 10.6.3 Latin America By Country Sales Analysis
    • 10.6.4 Brazil Sales Analysis
    • 10.6.5 Argentina Sales Analysis
    • 10.6.6 Peru Sales Analysis
    • 10.6.7 Chile Sales Analysis
    • 10.6.8 Rest of Latin America Sales Analysis
  • 10.7. Middle East & Africa Sales Analysis
    • 10.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 10.7.2 Middle East & Africa By Segment Sales Analysis
    • 10.7.3 Middle East & Africa By Country Sales Analysis
    • 10.7.4 Saudi Arabia Sales Analysis
    • 10.7.5 UAE Sales Analysis
    • 10.7.6 Israel Sales Analysis
    • 10.7.7 South Africa Sales Analysis
    • 10.7.8 Rest Of Middle East And Africa Sales Analysis

11. COMPETITIVE LANDSCAPE OF THE GUILLAIN-BARRE SYNDROME (GBS) COMPANIES

  • 11.1. Guillain-Barre Syndrome (GBS) Market Competition
  • 11.2. Partnership/Collaboration/Agreement
  • 11.3. Merger And Acquisitions
  • 11.4. New Product Launch
  • 11.5. Other Developments

12. COMPANY PROFILES OF GUILLAIN-BARRE SYNDROME (GBS) INDUSTRY

  • 12.1. Top Companies Market Share Analysis
  • 12.2. Market Concentration Rate
  • 12.3. AbbVie Inc.
    • 12.3.1 Company Overview
    • 12.3.2 Company Revenue
    • 12.3.3 Products
    • 12.3.4 Recent Developments
  • 12.4. Biogen Inc.
    • 12.4.1 Company Overview
    • 12.4.2 Company Revenue
    • 12.4.3 Products
    • 12.4.4 Recent Developments
  • 12.5. Cadila Healthcare Limited
    • 12.5.1 Company Overview
    • 12.5.2 Company Revenue
    • 12.5.3 Products
    • 12.5.4 Recent Developments
  • 12.6. CSL Behring LLC
    • 12.6.1 Company Overview
    • 12.6.2 Company Revenue
    • 12.6.3 Products
    • 12.6.4 Recent Developments
  • 12.7. F.Hoffmann-La Roche Ltd.
    • 12.7.1 Company Overview
    • 12.7.2 Company Revenue
    • 12.7.3 Products
    • 12.7.4 Recent Developments
  • 12.8. GSK Plc
    • 12.8.1 Company Overview
    • 12.8.2 Company Revenue
    • 12.8.3 Products
    • 12.8.4 Recent Developments
  • 12.9. Grifols SA
    • 12.9.1 Company Overview
    • 12.9.2 Company Revenue
    • 12.9.3 Products
    • 12.9.4 Recent Developments
  • 12.10. LGM Pharmaceuticals Inc.
    • 12.10.1 Company Overview
    • 12.10.2 Company Revenue
    • 12.10.3 Products
    • 12.10.4 Recent Developments
  • 12.11. Merck & Co. Inc.
    • 12.11.1 Company Overview
    • 12.11.2 Company Revenue
    • 12.11.3 Products
    • 12.11.4 Recent Developments
  • 12.12. Octapharma AG
    • 12.12.1 Company Overview
    • 12.12.2 Company Revenue
    • 12.12.3 Products
    • 12.12.4 Recent Developments
  • 12.13. Pfizer Inc.
    • 12.13.1 Company Overview
    • 12.13.2 Company Revenue
    • 12.13.3 Products
    • 12.13.4 Recent Developments
  • 12.14. Takeda Pharmaceutical Company Limited
    • 12.14.1 Company Overview
    • 12.14.2 Company Revenue
    • 12.14.3 Products
    • 12.14.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies